|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.63 USD | -2.95% |
|
+22.33% | -87.16% |
| 07-05 | Leerink Upgrades AN2 Therapeutics to Outperform Rating With $5 Price Target | MT |
| 07-03 | Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Price Target is $5 | MT |
AN2 Therapeutics, Inc.(NasdaqGS:ANTX) dropped from Russell 3000E Growth Index
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 18,353 PTS | +0.90% | +3.50% | - | ||
| 5,567 PTS | +0.54% | +1.95% | - | ||
| 2.63 USD | -2.95% | +22.33% | 78.45M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -87.16% | 78.45M | |
| +18.97% | 45.34B | |
| +42.21% | 40.42B | |
| -10.06% | 37.92B | |
| +31.15% | 31.75B | |
| -7.79% | 27.71B | |
| +13.32% | 26.52B | |
| +43.05% | 13.96B | |
| +31.28% | 12.44B | |
| -7.41% | 11.26B |
AN2 THERAPEUTICS, INC. 
